MedTech

Benchling is expanding into the early development market to accelerate the creation of breakthrough products

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformity required for compliance with regulations.

The market and society are putting unprecedented pressure on R&D companies to develop new products and get them to market faster. Vaccines typically take years to develop. But in developing COVID-19 vaccines and therapies, researchers have been able to get them ready for clinical trials in a matter of months. Faster time to market for innovative biotech products can mean that patients can receive new treatments for life-changing diseases faster, such as the COVID-19 vaccines. It can also mean producing more food with less energy, enriching consumer lives with ethically sourced products, and making businesses more climate-friendly.

The development of such complex, important products requires modern technologies. Different individual solutions for electronic laboratory notebooks (ELN), laboratory information management systems (LIMS) and laboratory execution systems (LES) form silos that exacerbate the challenges of complex collaboration. They force scientists to spend time comparing data between different systems instead of gaining important insights that accelerate product development.

With more than 600 customers spanning a wide range of company sizes, industries and scientific use cases, Benchling relies on customer partnerships to expand its product range. Here are examples of benchling customers who have improved their development speed, scientific knowledge and collaboration within their R&D organizations:

Syngenta is one of the world's largest producers of novel seeds. Worldwide, 35 percent of food is rendered unusable by pests and diseases. New biological solutions and better built-in defense mechanisms not only protect against food waste, but also reduce the need for harmful chemicals that pollute the environment.

Syngenta's work relies on scaling, as our researchers: internally test hundreds of thousands of seeds in a variety of growing environments. When we discover viable varieties that meet the needs of farmers, we need to replenish our seed stocks quickly for testing in laboratories, greenhouses and field trials around the world, “Thanks to benchling, we said goodbye to paper. Our global seed R&D teams can efficiently work together on a single platform to standardize the development of seed varieties from the laboratory to the test field. This has enabled us to restructure much of our work and accelerate the time-to-market for new seed products.

- Charlie Baxter, Head of Traits, Regulatory and Product Safety at Syngenta. 


New workflows: Benchling has expanded the workflows application to support collaboration between specialized R&D teams. Users can now coordinate tasks and processes across teams with full traceability, including methods, samples and inventory. Project managers gain insight into ongoing processes in order to reduce bottlenecks and increase productivity. Workflows help teams from research to development to work together more efficiently and to reach important milestones more quickly.

Structured Templates: With Benchling's new, more structured templates, product development teams can easily create common, standardized processes for repeatable experiments, analytical tests, QC protocols and more. These procedures can be regulated in a targeted manner in order to meet compliance requirements.

Validated cloud: At the beginning of 2021, Benchling switched to a validated cloud in order to be able to provide the platform for customers in a GxP environment.

About Benchling
Benchling is the pioneer for the R&D cloud, software that supports the biotechnology industry. Globally, more than 200,000 scientists in over 600 companies and 7,000 research institutions use Benchling's R&D cloud to make groundbreaking discoveries and bring the next generation of drugs, food and materials to market faster than ever before. The R&D cloud is helping these companies modernize their scientific processes and accelerate collaboration so they can transform the complexities of biology into world-changing results.

Spotlight

Spotlight

Related News

Medical

Vernal Biosciences Announces Strategic Leadership Appointments to Drive Growth in mRNA and LNP Formulation

Vernal Biosciences | January 03, 2024

<p> Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of Sven Lee, Chief Commercial Officer, and Richard P. Hamel, Chief Financial Officer to its leadership team. Both distinguished leaders will strengthen Vernal&rsquo;s position as a premier mRNA and LNP Contract Development and Manufacturing Organization (CDMO) while using their deep experience to deliver Vernal&rsquo;s integrated mRNA manufacturing solutions to a growing marketplace.</p> <p> Chief Commercial Officer - Sven Lee</p> <p> Sven will lead the Commercial team, including business development, marketing, technical sales, and alliance management. His team will help customers define their manufacturing needs and provide creative solutions that leverage Vernal&rsquo;s innovative technologies and manufacturing operations. Sven has a 30-year track record achieving remarkable business growth across the biotech and pharma sectors. Prior to joining Vernal, Sven was a Board Member and the Chief Commercial Officer at BioCina, an Australian based CDMO. Prior to BioCina, Sven spent six years as the Chief Business Officer of Abzena, a fully integrated, global biologics and bioconjugate CDMO. Sven has also held prominent roles in sales, marketing, and strategic planning at other CDMOs and life sciences companies including Global VP of Business Development at Catalent Biologics, Sr. Director of Global Business Development &amp; Sales at TerumoBCT, Crucell (now Janssen), and Biogen.</p> <p> As Chief Commercial Officer, Lee says, &ldquo;I am thrilled to be a part of a dynamic team specializing in high purity mRNA and LNP solutions for client partners in the rapidly advancing field of biotechnology of vaccines and therapeutic development for clinical trials and commercial use.&rdquo;</p> <p> Chief Financial Officer &ndash; Richard P. Hamel</p> <p> Richard will be responsible for Vernal&rsquo;s finance strategy and will lead the finance organization, including planning, treasury, tax and reporting, Richard is an accomplished financial executive with over 25 years of experience managing finance teams, improving business performance, and developing systems, processes, and procedures to streamline operations for high growth life science companies. Most recently, Richard was CFO at ReciBioPharm where he played a key role in integrating and managing several business units within ReciBioPharm. Prior to joining ReciBioPharm, he was CFO at United BioSource in Blue Bell, PA helping carve out the business from Express Scripts and building a stand-alone finance organization. Prior to joining United BioSource, Richard spent over seven years at inVentiv Health/Syneos in various financial roles of increasing responsibility including finance, shared services and treasury. Earlier in his career, Richard held a range of finance positions at ThermoFisher, AB Volvo, Kodak, Diageo and EY.</p> <p> As CFO, Richard will support Vernal Biosciences in achieving its ambitious goals and driving long-term success. &ldquo;I am excited to join the Vernal team and apply my experience to further bolster the company&rsquo;s already strong mRNA and LNP portfolio and further expand its unique capabilities,&rdquo; said Hamel.</p> <p> CEO and Founder of Vernal Biosciences, Christian Cobaugh says, &ldquo;On behalf of all Vernal employees and our investors, I am excited to welcome Sven and Rich to Vernal&rsquo;s talented leadership team. Their collective experience and success that they bring to Vernal and our clients complements our expansion, including the recent addition of our GMP facilities and operations. Sven has spent most of his career helping customers find creative solutions in clinical manufacturing and Rich has successfully built and integrated several businesses in the life sciences sector, from early stage to global scale. Their additions to our team will help Vernal democratize access to high purity mRNA and LNPs for all stages of research and development.&rdquo;</p> <p> <strong>About Vernal Biosciences</strong></p> <p> Vernal Biosciences is a leading CDMO specializing in mRNA and LNP manufacturing. Vernal provides comprehensive high purity platform manufacturing solutions for mRNA-based medicines and vaccines, from research to clinical development. Our dedicated team of experts, our platform solutions, and GMP facility show our commitment to our partners, enabling them to focus on accelerating their programs to clinical development to improve patient lives.</p>

Read More

Medical

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine

Capricor Therapeutics | January 24, 2024

Capricor Therapeutics a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that Capricor’s proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will conduct a Phase 1 clinical study with Capricor’s StealthX™ vaccine, subject to regulatory approval. NIAID's Division of Microbiology and Infectious Diseases (DMID) would oversee the study. “We are extremely pleased with the external support from the NIH, which highlights the clinical potential of our StealthX™ exosome platform technology and provides non-dilutive support for the advancement of our vaccine candidate,” said Linda Marbán, Ph.D., Capricor’s chief executive officer. “Our proprietary vaccine is multivalent, delivering both the highly mutagenic S protein (Spike) and the more stable N protein (Nucleocapsid) which potentially may offer broader and longer lasting immunity against SARS-CoV-2. We view the NIH SARS-CoV-2 project as the first clinical step towards development of a next generation vaccine platform that may be extended to other infectious diseases. Our platform is designed to combine the speed of response of an mRNA vaccine with the potential efficacy of a protein vaccine. Further, our StealthX™ vaccine is free of both adjuvant and lipid nanoparticles and in preclinical studies has generated a strong immune response at low doses. We believe our StealthX™ vaccine may offer a clinically meaningful alternative for highly mutating or novel infectious agents.” Dr. Marbán continued, “This is the opportunity we have been waiting for as it allows the exosome technology to be brought into the clinic as we continue to focus our resources on CAP-1002 for the treatment of Duchenne muscular dystrophy. Beyond SARS-CoV-2, we look forward to exploring the potential therapeutic utility of this platform, and more broadly, expanding our pipeline into therapeutics and future partnership opportunities.” About Capricor’s StealthX™ Vaccine The StealthX™ vaccine is a proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface. Preclinical results from murine and rabbit models published in Microbiology Spectrum, showed the StealthX™ vaccine, resulted in robust antibody production, potent neutralizing antibodies, a strong T-cell response and a favorable safety profile. These effects were obtained with administration of only nanogram amounts of protein and without adjuvant or synthetic lipid nanoparticles (LNPs). Exosomes offer a new antigen delivery system that potentially could be utilized to rapidly generate multivalent protein-based vaccines. Exosomes, first identified as extracellular vesicles, are small vesicles enriched in specific subsets of proteins, RNAs and lipids and responsible for cell-to-cell communication. About Capricor Therapeutics Capricor Therapeutics, Inc. is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy currently in Phase 3 clinical development for treating Duchenne muscular dystrophy (DMD). Further, Capricor has entered into a partnership for the exclusive commercialization and distribution of CAP-1002 for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Capricor is also developing its exosome technology as a potential next-generation therapeutic platform. Our proprietary StealthX™ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases.

Read More

Medical

CCM Biosciences Announces Launch of 5Prime Sciences Business Unit

CCM Biosciences | January 01, 2024

Diversified biotechnology company CCM Biosciences (CCM Bio) announced the launch of its business unit CCM 5Prime Sciences (5Prime) focused on the development and application of proprietary technology in the domain of DNA biotechnology. 5Prime’s technology platform includes multiple patent-protected, globally commercialized compositions and methods for molecular cloning, next-generation DNA sequencing and molecular diagnostics. 5Prime has two focus areas: 1) in vitro diagnostic (IVD) tests: a wide array of companion diagnostics (CDx) tests for targeted cancer, rare disease, and prenatal/preimplantation diagnostics, developed using the droplet digital Polymerase Chain Reaction (ddPCR) and Next-Generation Sequencing (NGS) methodologies, which accompany the personalized medicine therapeutic (Rx) pipeline of CCM Bio; 2) synthetic biology: engineered DNA- and RNA-manipulating enzymes that improve upon the enzymes used in IVD tests, in PCR reagents, and also in enzymatic DNA/RNA synthesis. Proven technology behind market-leading DNA sequencing products and diagnostic tests; including one of the 5 highest revenue-generating technologies invented in the history of Princeton University Focus areas 1 and 2 are based on the company’s patented technology originating in the PhD thesis work of Co-Founder and CEO Dr. Raj Chakrabarti at Princeton University. According to the Princeton University Office of Technology Licensing, patents in this portfolio, which are now controlled by 5Prime, are among the top 5 revenue-generating patents in the history of the university, having been commercialized in collaboration with companies such as Celera Diagnostics, Quest Diagnostics, Abbott, New England Biolabs, and Toyobo Life Sciences. Diagnostic tests and products based on the company’s intellectual property include the XSense test from Quest Diagnostics, which is the leading DNA-based carrier screening test for autism (Fragile X syndrome); and the Q5 polymerase kit marketed by New England Biolabs, which is the leading high-fidelity polymerase kit for DNA sequencing. In the context of molecular diagnostics, NGS is typically applied to diagnose in high-throughput the patterns of DNA mutations in genes. A related method called RNA-Seq, which applies NGS to RNA rather than DNA to measure real-time gene expression levels, has emerged as a foundation for modern personalized medicine. However, a notorious difficulty in both traditional NGS and RNA-Seq is sequence bias, which results in inaccurate estimates of the relative copy numbers of different genes and associated disease-causing mutations, and which has limited the transformative potential of these methods. ddPCR is a sensitive method for diagnosing mutations in specific disease-associated genes that is also limited by problems of sequence bias. 5Prime’s technology enables the efficient polymerization and amplification of nearly any DNA or RNA sequence to overcome sequence bias in nucleic acid amplification and associated diagnostic methods like NGS and ddPCR, the global markets for which were valued at $10B and $6B, respectively, in 2022 and expected to surpass $44B and $14B, respectively, by 2032. Its state-of-the-art synthetic biology platform for polymerase enzyme engineering generates proprietary polymerases with optimal properties for NGS or PCR-based diagnostic tests, by applying machine learning algorithms to the big data generated from ultrahigh-throughput, microfluidic experimental screening of enzyme activity. In addition, the company’s technology platform applies proprietary nonaqueous media and computational systems biology methods in conjunction with such enzymes to dramatically improve nucleic acid polymerization and amplification efficiency. About CCM Biosciences CCM Biosciences, Inc. is a biotechnology company dedicated to discovering and developing novel drugs - including small molecules, gene therapies, biologics, and nanomedicines - as well as associated companion diagnostics. CCM Bio’s patented molecular discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, American Chemical Society journals and Nature Publishing Group journals. CCM Bio is partnered with the global chemical and pharmaceutical services company PMC Group, Inc. for fully integrated discovery, development and manufacturing of drugs and diagnostics.

Read More